istaroxime

Phase 2Small molecule

WWindtree Therapeutics

istaroxime is one of 23 small molecule programs targeting Heart Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Heart FailurePhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Brethine

Sanofi

Preclinical

1 2

Amidate

Pfizer

Preclinical

1 3

LCZ696

Novartis

Preclinical

15 4

Zemplar

AbbVie

Preclinical

—5

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 6

Xifaxan

SSalix

Preclinical

2 7

Zoloft

VViatris Specialty LLC

Preclinical

2 8

Coumadin

AAbbott

Preclinical

1 9

istaroxime

WWindtree Therapeutics

Phase 2

3 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Safety and Efficacy

NCT05975021

Clinical

Trials by Indication[1]

Heart Failure3 trials

The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure

Completed·WWindtree Therapeutics·Phase 2·NCT02617446·120 enrolled

Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure

Withdrawn·DDebiopharm International SA·Phase 1·NCT00869115

Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients

Withdrawn·DDebiopharm International SA·Phase 2·NCT00838253

Safety and Efficacy2 trials

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

Completed·WWindtree Therapeutics·Phase 2·NCT04325035·90 enrolled

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

Active, not recruiting·WWindtree Therapeutics·Phase 1/2·NCT05975021·20 enrolled

Infusion1 trial

Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

Completed·LLee's Pharmaceutical Limited·Phase 1·NCT02477449·32 enrolled

Hemodynamic Response1 trial

Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a

Completed·BBenjamin Levine·Phase 1·NCT02772068·26 enrolled

Hemodynamic1 trial

A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function

Completed·Ssigma-tau i.f.r. S.p.A.·Phase 2·NCT00616161·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for istaroxime. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — istaroxime compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for istaroxime. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Windtree Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWindtree Therapeutics

istaroxime

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Heart Failure3 trials

Safety and Efficacy2 trials

Infusion1 trial

Hemodynamic Response1 trial

Hemodynamic1 trial

References

Drug Info

Quick Facts

Related News